AEON Biopharma, Inc.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company that reached the public markets through a SPAC business combination, with the underlying blank-check vehicle registered under CIK 0001837607 in 2021 during the height of the SPAC issuance cycle. Operating in the healthcare and life sciences sector, the company focuses on botulinum toxin therapeutics and has maintained its SEC reporting obligations as a post-merger public issuer. On May 14, 2026, AEON Biopharma filed an 8-K current report disclosing a material corporate event. For complete filing history, sponsor details, deal analytics, and real-time alerts on AEON Biopharma and the broader SPAC universe, sign up for full data access at SpacDesk.